- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02583659
The First-line Combined Chemotherapy for Advanced Gastric Cancer: A Prospective Observational Clinical Study
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Establish a clinical database for the advanced gastric cancer patients treated with first-line combined chemotherapy in Tongji hospital.
1.1.Data including age, gender, smoking state, karnofsky performance score(KPS), disease history, clinical stage, primary tumor site, metastasis site, surgery, first-line chemotherapy, therapy after failure of first-line treatment, radiotherapy, toxicity, survival time, the time of free of progress, response were collected.
1.2.The peripheral blood samples were collected for further biomarker reserch.
- Kaplan-Meier and Cox model will be used to analyze the overall survival(OS) and progression-free survival(PFS) of advanced gastric cancer.
- Extract Deoxyribonucleic acid(DNA) from the the peripheral blood and research biomarkers related to the first-line combined chemotherapy for AGC.
Type d'étude
Inscription (Anticipé)
Contacts et emplacements
Lieux d'étude
-
-
Hubei
-
Wuhan, Hubei, Chine, 430030
- Recrutement
- Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
-
Chercheur principal:
- Xianglin Yuan, MD,PHD
-
Contact:
- Xianglin Yuan, MD,PHD
- Numéro de téléphone: 1 13667241722
- E-mail: yxl@medmail.com.cn
-
Contact:
- Suxian Wei, Master
- Numéro de téléphone: 1 15927421058
- E-mail: wsxattj@126.com
-
Sous-enquêteur:
- Suxian Wei, MD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Histopathology or cytopathology proven gastric cancer or gastroesophageal adenocarcinoma;
- Unresectable locally advanced, or recurrent, or metastasis disease;
- Chemotherapy-naive or disease progress at least 6 months after adjuvant chemotherapy completed.
- Life expectancy of at least 3 months;
- ECOG score 0-2;
- Voluntarily signed the informed consent.
Exclusion criteria:
- Previously treated with first-line chemotherapy;
- First-line chemotherapy with single drug.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
---|
Combined chemotherapy
AGC patients treated with first-line combined chemotherapy
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
---|---|
Overall survival(OS) . overall survival Overall survival(OS)
Délai: From date of enrollment until the date of death from any cause, assessed up to 60 months
|
From date of enrollment until the date of death from any cause, assessed up to 60 months
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
---|---|
Progression-free survival(PFS)
Délai: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months
|
From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months
|
Objective response rate(ORR)
Délai: The sum of complete remission (CR) rate and partial remission (PR) rate. Response will be measured through first-line treatment completion, up to 1 year
|
The sum of complete remission (CR) rate and partial remission (PR) rate. Response will be measured through first-line treatment completion, up to 1 year
|
Disease control rate(DCR)
Délai: The sum of CR rate, PR rate and stable disease(SD) rate. Response will be measured through first-line treatment completion, up to 1 year
|
The sum of CR rate, PR rate and stable disease(SD) rate. Response will be measured through first-line treatment completion, up to 1 year
|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Délai: Through first-line treatment completion,up to 24 weeks.
|
Through first-line treatment completion,up to 24 weeks.
|
Collaborateurs et enquêteurs
Les enquêteurs
- Chercheur principal: Xianglin Yuan, MD,PHD, Tongji Hospital
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- TJCC004
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Cancer de l'estomac
-
North Dakota State UniversityNational Institutes of Health (NIH)ComplétéRoux en Y Gastric Bypass ChirurgieÉtats-Unis
-
Natalia Valadares de MoraesUniversity of Sao Paulo; Fundação de Amparo à Pesquisa do Estado de São PauloInscription sur invitationImpact de la chirurgie bariatrique sur l'étude pharmacocinétique de la simvastatine et du carvédilolObésité | Chirurgie bariatrique | Roux-en Y Gastric BypassÉtats-Unis
-
AstraZenecaRecrutementAdv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian CancerEspagne, États-Unis, Belgique, Royaume-Uni, France, Hongrie, Canada, Corée, République de, Australie